Different sociodemographic groups, especially racial and ethnic minorities, are less likely to receive timely breast cancer diagnostic services after an abnormal screening mammogram, according to a ...

For this retrospective study, the authors examined data on more than 3 million screening mammographies for more than 1 ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies.

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Breast cancer remains a global challenge, marked by diverse patient responses to treatments and varying prognoses. The ...

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

Women whose breast cancers need estrogen to grow are often treated for five or more years with medications to lower estrogen ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...